Is DFS an Appropriate Surrogate for OS in Early HER2+ Breast Cancer?

Article

The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.

Disease-free survival has a reasonably high correlation with overall survival in trials of patients with early HER2-positive breast cancer treated with adjuvant trastuzumab, according to a new meta-analysis. The findings suggest that disease-free survival (DFS) can continue to be used as a surrogate endpoint in this field.

“The development of novel adjuvant regimens is a lengthy process, and the analysis of overall survival requires a long follow-up,” wrote study authors led by Everardo D. Saad, MD, of the International Drug Development Institute in Louvain-La-Neuve, Belgium. “Although DFS has often been used as the primary endpoint in adjuvant trials of breast cancer, to our knowledge it has not been formally validated in this setting.”

The researchers conducted a review and meta-analysis evaluating the role of DFS as a surrogate for overall survival (OS) in the adjuvant treatment of HER2-positive breast cancer. They investigated both patient-level associations between those outcomes, meaning whether a patient with prolonged DFS would also expect to have prolonged OS, and trial-level associations, meaning whether treatment-induced changes in the surrogate endpoint are mirrored by such changes in the final endpoint. The results of the analysis were published in Lancet Oncology.

The study included a total of 8 trials encompassing 21,480 patients; the trials included 12 contrasts between varying therapies, including between chemotherapy or observation plus trastuzumab, between 12 months and a shorter course of trastuzumab, or in one case, between lapatinib and that agent plus trastuzumab.

The patient-level associations between DFS and OS were “strong,” according to the authors. The correlation coefficient for this measure was 0.90 (95% CI, 0.89–0.90). For trial-level associations, the coefficient of determination (R2) was 0.75 (95% CI, 0.50–1.00). A post-hoc reduced set analysis that excluded one trial due to methodological limitations yielded an R2 of 0.84 (95% CI, 0.67–1.00).

The authors noted that their analysis is limited by the reliance on the individual trials included and some of their methodological differences. Still, they wrote that “our results suggest that DFS might have good overall statistical validity to be used as a surrogate for OS in the adjuvant treatment of HER2-positive early breast cancer.”

In an accompanying editorial, Eitan Amir, PhD, of the Princess Margaret Cancer Centre and the University of Toronto, wrote that the inclusion of the patient- and trial-level analyses is a “major strength of the analysis and provides robust support for the adequate surrogacy of DFS and OS in HER2-positive early-stage breast cancer.”

He noted that it remains to be seen whether the data from this study can be extrapolated to other settings. For example, triple-negative breast cancer is associated with DFS event rates similar to those seen in untreated HER2-positive breast cancer, but “the magnitude of relative treatment effect in this subgroup is smaller.” In other settings, lower event rates might result in a poorer performance of the surrogate endpoint.

“Attempts to validate DFS as a surrogate for OS should be pursued in a broader group of breast cancers while ensuring ... that assessment includes not only the strength and consistency of correlation between the surrogate and definitive endpoints at the trial level, but also the prediction of the net effect of treatment at a patient level,” Amir wrote.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content